A randomized trial comparing amitriptyline versus topiramate for the prophylaxis of chronic daily headache in pediatric patients.
Int J Neurosci
; 123(8): 553-6, 2013 Aug.
Article
em En
| MEDLINE
| ID: mdl-23421731
ABSTRACT
OBJECTIVE:
the goal of this prospective and double-blind study was to compare the efficacy of amitriptyline and topiramate for the prevention of pediatric chronic daily headache (CDH). RESEARCH DESIGN ANDMETHODS:
fifty-seven children (aged 9-16 yr) diagnosed with CDH were randomly assigned to two groups group A (n = 29 patients) received amitriptyline 0.5 mg/kg/d and group B (n = 28 patients) received topiramate 25 mg/d increasing up to 100 mg/d according to patient response. Treatment response was monitored for at least 4 months.RESULTS:
fifty-five percent of the patients in group A responded to amitriptyline and 61% of patients in group B responded to topiramate as defined by a reduction of more than 50% in monthly headache frequency. There was no significant difference in responder rate or adverse event rate between the two groups (p > 0.05). By the end of the 4-month treatment period, there were no significant differences in the final average severity and monthly frequency of headaches between treatment groups.CONCLUSION:
these results suggest that the efficacy and tolerability of topiramate is equivalent to that of amitriptyline for reducing the frequency of headache in pediatric CHD patients.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Analgésicos não Narcóticos
/
Transtornos da Cefaleia
/
Frutose
/
Amitriptilina
/
Anticonvulsivantes
Tipo de estudo:
Clinical_trials
Limite:
Adolescent
/
Child
/
Female
/
Humans
/
Male
Idioma:
En
Revista:
Int J Neurosci
Ano de publicação:
2013
Tipo de documento:
Article
País de afiliação:
Turquia